Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration has accepted Eisai’s Supplemental Biologics License Application for monthly lecanemab-irmb intravenous maintenance dosing.
DeepQure, a Seoul based medical device company with a novel, extravascular solution for renal denervation, announced initiation of its Early Feasibility Study for the HyperQure™ system following FDA IDE approval.
J. Robert Oppenheimer, conocido como el “Padre de la Bomba Atómica”, es una figura central en la historia de la ciencia y la tecnología del siglo XX. Su vida y obra no solo marcaron un hito en la física moderna, sino que también dejaron una huella imborrable en …
J. Robert Oppenheimer: El padre de la bomba atómica Read More »
LSD, ketamine, ibogaine and related treatments are moving forward in clinical trials for substance use disorders, including alcohol use disorder and opioid use disorder.
Psychedelic Therapies Could Soon Break Through Against Addiction Read More »
The FDA currently does not recommend using changes in lean mass as an endpoint in clinical trials for weight loss drugs. Should it?
Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs Read More »
Tempting as it may be to turn to full automation to meet burdensome requirements, the potential for hallucination and other issues means biopharma companies must proceed with caution.
Opinion: GenAI Is Not a One-Size-Fits-All Solution for Regulatory Operations Read More »
While more programs now involve candidates with different targets, experts say anti-amyloid therapies will remain a primary player in treating the memory-robbing disease.
Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments Read More »
Los médicos recomiendan precaución ya que las bebidas energéticas pueden desencadenar arritmias cardíacas potencialmente mortales en pacientes con enfermedades cardíacas genéticas.
“Alimentos arritmogénicos” | Bebidas energizantes y riesgo de arritmias cardíacas Read More »
Revisión sobre avances recientes en el manejo de la fibrosis quística y sus efectos en el cuidado clínico
Una revisión actualizada y orientada a la práctica | Fibrosis quística Read More »
Baxter declined to comment on whether vulnerabilities identified in two Welch Allyn products were due to a breach or cyberattack.
CISA warns of cybersecurity risks in Baxter products Read More »
